{
    "organizations": [],
    "uuid": "96a180092a4a1e497bb8600143047f43b88ebe3b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-loxo-oncology-and-illumina-to-part/brief-loxo-oncology-and-illumina-to-partner-on-developing-pan-cancer-companion-diagnostics-idUSFWN1RN07L",
    "ord_in_thread": 0,
    "title": "BRIEF-Loxo Oncology And Illumina To Partner On Developing Pan Cancer Companion Diagnostics",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 10 (Reuters) - Loxo Oncology:\n* LOXO ONCOLOGY AND ILLUMINA TO PARTNER ON DEVELOPING NEXT-GENERATION SEQUENCING-BASED PAN-CANCER COMPANION DIAGNOSTICS\n* LOXO ONCOLOGY-PARTNERSHIP TO SEEK APPROVAL FOR VERSION OF ILLUMINA TRUSIGHT TUMOR 170 AS COMPANION DIAGNOSTIC FOR LAROTRECTINIB, LOXO-292 ACROSS TUMORS\n* LOXO ONCOLOGY - COMPANIES ALSO PLANNING TO BROADEN CLINICAL UTILITY OF FULL PANEL BY OBTAINING REGULATORY APPROVAL FOR OTHER ASSAY CONTENT Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-10T19:27:00.000+03:00",
    "crawled": "2018-04-11T18:14:44.018+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "loxo",
        "oncology",
        "loxo",
        "oncology",
        "illumina",
        "partner",
        "developing",
        "companion",
        "diagnostics",
        "loxo",
        "seek",
        "approval",
        "version",
        "illumina",
        "trusight",
        "tumor",
        "companion",
        "diagnostic",
        "larotrectinib",
        "across",
        "tumor",
        "loxo",
        "oncology",
        "company",
        "also",
        "planning",
        "broaden",
        "clinical",
        "utility",
        "full",
        "panel",
        "obtaining",
        "regulatory",
        "approval",
        "assay",
        "content",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}